{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:04:03Z","timestamp":1790208243282,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-58927-8","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T21:16:50Z","timestamp":1782681410000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of elevated liver enzymes and its associated factors among people living with HIV on dolutegravir-based ART at Debre Markos Comprehensive Specialized Hospital, Ethiopia"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6700-9972","authenticated-orcid":false,"given":"Mohammed","family":"Jemal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melkamu","family":"Tilahun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabarak","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belayneh","family":"Yosef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adane","family":"Adugna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"issue":"47","key":"58927_CR1","doi-asserted-by":"publisher","first-page":"e35910","DOI":"10.1097\/MD.0000000000035910","volume":"102","author":"SN Echefu","year":"2023","unstructured":"Echefu, S. N., Udosen, J. E., Akwiwu, E. C., Akpotuzor, J. O. & Obeagu, E. I. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine 102 (47), e35910 (2023).","journal-title":"Medicine"},{"key":"58927_CR2","unstructured":"Eggleton, J. S. & Nagalli, S. Highly active antiretroviral therapy (HAART) (StatPearls Publishing, 2023)."},{"issue":"1","key":"58927_CR3","first-page":"36","volume":"5","author":"N Kontorinis","year":"2003","unstructured":"Kontorinis, N. & Dieterich, D. Hepatotoxicity of antiretroviral therapy. AIDS Rev. 5 (1), 36\u201343 (2003).","journal-title":"AIDS Rev."},{"issue":"1 Suppl","key":"58927_CR4","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1016\/j.jhep.2005.11.027","volume":"44","author":"M N\u00fa\u00f1ez","year":"2006","unstructured":"N\u00fa\u00f1ez, M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J. Hepatol. 44 (1 Suppl), S132\u2013S139 (2006).","journal-title":"J. Hepatol."},{"key":"58927_CR5","doi-asserted-by":"crossref","unstructured":"Gebremicael, G., Tola, H. H., Gebreegziaxier, A., Kassa, D. J. H. A. R. & Care, P. Incidence of hepatotoxicity and factors associated during highly active antiretroviral therapy in people living with HIV in Ethiopia: A prospective cohort study. 329\u2013336 (2021).","DOI":"10.2147\/HIV.S283076"},{"key":"58927_CR6","doi-asserted-by":"crossref","unstructured":"Strauss, K. E., Phoswa, W. N., Hanser, S. & Mokgalaboni, K. HIV infection and antiretroviral therapy impair liver function in people living with HIV: Systematic review and meta-analysis. Pharmaceuticals (Basel Switzerland) 18(7). (2025).","DOI":"10.3390\/ph18070955"},{"issue":"1","key":"58927_CR7","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1186\/s12879-022-07838-w","volume":"22","author":"O Mohammed","year":"2022","unstructured":"Mohammed, O. et al. Prevalence of hepatotoxicity among HIV-infected patients in Ethiopia: a systematic review and meta-analysis. BMC Infect. Dis. 22 (1), 826 (2022).","journal-title":"BMC Infect. Dis."},{"key":"58927_CR8","unstructured":"Article, W. H. O. J. V. New report documents increase in HIV drug resistance to dolutegravir. 2024. (2024)."},{"key":"58927_CR9","unstructured":"Segona, B. et al. Dolutegravir induced sub-acute hepatic failure in HIV positive treatment na\u00efve man in Botswana. (2019)."},{"key":"58927_CR10","doi-asserted-by":"crossref","unstructured":"Nhean, S., Yoong, D., Wong, D. K., Gough, K. & Tseng, A. L. J. A. Probable hepatotoxicity with dolutegravir: Report of two cases and review of the literature. 33(7), 1261\u20131263. (2019).","DOI":"10.1097\/QAD.0000000000002191"},{"key":"58927_CR11","doi-asserted-by":"crossref","unstructured":"Christensen, E. S., Jain, R. & Roxby, A. C. (eds) Abacavir\/Dolutegravir\/Lamivudine (Triumeq)\u2013Induced Liver Toxicity in a Human Immunodeficiency Virus\u2013Infected Patient. Open forum infectious diseases (Oxford University Press US, 2017).","DOI":"10.1093\/ofid\/ofx122"},{"key":"58927_CR12","doi-asserted-by":"crossref","unstructured":"Wang, B. et al. Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature. 29(4), 414\u2013417 (2018).","DOI":"10.1177\/0956462417734099"},{"key":"58927_CR13","doi-asserted-by":"crossref","unstructured":"Rossotti, R. et al. Severe cholestatic hepatitis related to abacavir\/lamivudine\/dolutegravir antiretroviral treatment in a HIV-1 infected subject. 32(12), 1727\u20131729 (2018).","DOI":"10.1097\/QAD.0000000000001890"},{"key":"58927_CR14","doi-asserted-by":"crossref","unstructured":"Ejike, O. J. et al. Freeman10 IEGJIJoM, research C. Effects of dolutegravir and protease inhibitors based regimen on renal and liver function markers of HIV patients attending daughters of charity. Hosp. Abuja 13. (2025).","DOI":"10.14741\/ijmcr\/v.13.1.4"},{"issue":"2","key":"58927_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.61186\/jcbr.8.2.28","volume":"8","author":"O Bola Odegbemi","year":"2024","unstructured":"Bola Odegbemi, O., Folaranmi Olaniyan, M. & Abidemi Muhibi, M. Impact of tenofovir, lamivudine, and dolutegravir on liver function in HIV-positive individuals in Southern Nigeria %J. J. Clin. Basic. Res. 8 (2), 28\u201333 (2024).","journal-title":"J. Clin. Basic. Res."},{"key":"58927_CR16","doi-asserted-by":"crossref","unstructured":"Cesar, J. J. et al. Ceccato MdGBJR, Society, Development. Avalia\u00e7\u00e3o laboratorial da fun\u00e7\u00e3o hep\u00e1tica em pessoas iniciando a terapia antirretroviral com esquemas contendo Dolutegravir ou Efavirenz (estudo de coorte em Belo Horizonte, 2022).","DOI":"10.33448\/rsd-v11i13.35082"},{"issue":"6","key":"58927_CR17","first-page":"e62522","volume":"16","author":"K Joshi","year":"2024","unstructured":"Joshi, K., Shinde, S., Karatela, S. & Mulkalwar, A. Clinical Profile and Adverse Effects of Dolutegravir Treatment in HIV-Positive Patients: A Prospective Observational Study. Cureus 16 (6), e62522 (2024).","journal-title":"Cureus"},{"issue":"1","key":"58927_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12981-022-00442-7","volume":"19","author":"A Namulindwa","year":"2022","unstructured":"Namulindwa, A., Wasswa, J. H., Muyindike, W., Tamukong, R. & Oloro, J. Prevalence and factors associated with adverse drug events among patients on dolutegravir-based regimen at the Immune Suppression Syndrome Clinic of Mbarara Regional Referral Hospital, Uganda: a mixed design study. AIDS Res. therapy. 19 (1), 18 (2022).","journal-title":"AIDS Res. therapy"},{"issue":"1","key":"58927_CR19","doi-asserted-by":"publisher","first-page":"28013","DOI":"10.1038\/s41598-025-13504-3","volume":"15","author":"F Abraham","year":"2025","unstructured":"Abraham, F., Toma, A., Balcha, T. & Tigabu, B. M. Drug induced liver injury in HIV patients on dolutegravir based antiretroviral therapy regimens in Wolaita Sodo comprehensive specialized hospital. Sci. Rep. 15 (1), 28013 (2025).","journal-title":"Sci. Rep."},{"issue":"12","key":"58927_CR20","doi-asserted-by":"publisher","first-page":"e33054","DOI":"10.1016\/j.heliyon.2024.e33054","volume":"10","author":"EF Mengistu","year":"2024","unstructured":"Mengistu, E. F., Malik, D. T., Molla, M. D., Adugna, A. & Jemal, M. Liver function tests, CD4(+) counts, and viral load among people living with HIV on dolutegravir compared to efavirenz-based cART; a comparative cross-sectional study. Heliyon 10 (12), e33054 (2024).","journal-title":"Heliyon"},{"issue":"1","key":"58927_CR21","first-page":"2","volume":"13","author":"A Zeleke","year":"2020","unstructured":"Zeleke, A., Misiker, B. & Yesuf, T. A. J. B. R. N. Drug-induced hepatotoxicity among TB\/HIV co-infected patients in a referral hospital. Ethiopia 13 (1), 2 (2020).","journal-title":"Ethiopia"},{"key":"58927_CR22","doi-asserted-by":"crossref","unstructured":"Ganesan, M. et al. Alcohol metabolism potentiates HIV-induced hepatotoxicity: contribution to end-stage liver disease. Biomolecules 9(12). (2019).","DOI":"10.3390\/biom9120851"},{"key":"58927_CR23","unstructured":"Ngah, Y. E. et al. Incidence and risk factors of combined-antiretroviral therapy-induced hepatotoxicity among HIV patients at the Bali District Hospital, Cameroon. 16, 384339 (2024)."},{"key":"58927_CR24","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Ayala, P. et al. Risk factors for drug-induced liver injury in people with HIV on anti-tuberculosis treatment. Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica 503041 (2025).","DOI":"10.1016\/j.eimc.2025.503041"},{"key":"58927_CR25","doi-asserted-by":"crossref","unstructured":"Benedicto, A. M. et al. NNRTI and liver damage: evidence of their association and the mechanisms involved. 10(7), 1687 (2021).","DOI":"10.3390\/cells10071687"},{"key":"58927_CR26","doi-asserted-by":"crossref","unstructured":"Wondifraw Baynes, H. et al. Assessment of the effect of antiretroviral therapy on renal and liver functions among HIV-infected patients: a retrospective study. HIV\/AIDS (Auckland, NZ). 9, 1\u20137 (2017).","DOI":"10.2147\/HIV.S120979"},{"issue":"1","key":"58927_CR27","doi-asserted-by":"publisher","first-page":"8473","DOI":"10.1038\/s41598-024-57900-7","volume":"14","author":"T Darge","year":"2024","unstructured":"Darge, T., Babusha, A., Chilo, D., Dukessa, A. & Teferi, S. Predictors of severe hepatotoxicity among retroviral infected adults on HAART regimen in Ilubabor Zone, Southwest Ethiopia. Sci. Rep. 14 (1), 8473 (2024).","journal-title":"Sci. Rep."},{"key":"58927_CR28","unstructured":"Guidance, F. For industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials (US Department of Health and Human Services, 2007)."},{"key":"58927_CR29","unstructured":"EPHA. On alcohol, substance, khat and tobacco. In 22nd Annual Conference of EPHA2012."},{"key":"58927_CR30","first-page":"232595822514009","volume":"24","author":"M Jemal","year":"2025","unstructured":"Jemal, M. et al. Magnitude of hyperuricemia and its associated factors among people living with human immunodeficiency virus who enrolled in first-line antiretroviral therapy in Amhara region. Ethiopia 24, 23259582251400988 (2025).","journal-title":"Ethiopia"},{"key":"58927_CR31","doi-asserted-by":"crossref","unstructured":"Gebrie, A. J. P. O. Hypertension among people living with human immunodeficiency virus receiving care at referral hospitals of Northwest Ethiopia: A cross-sectional study. 15(8), e0238114 (2020).","DOI":"10.1371\/journal.pone.0238114"},{"key":"58927_CR32","unstructured":"Vaillant, A. A. J. & Naik, R. HIV-1\u2013associated opportunistic infections (StatPearls Publishing, 2023)."},{"key":"58927_CR33","unstructured":"Capro, J. Chronic diseases: Its impact on individuals for socioeconomic well being. Acute Chronic Disease Rep. 8(1) (2024)."},{"key":"58927_CR34","unstructured":"Consultation WJRoaWECGWHO. Waist circumference and waist-hip ratio. 8\u201311. (2008)."},{"key":"58927_CR35","unstructured":"W. H. O. Waist circumference and waist\u2013hip ratio. (2008)."},{"key":"58927_CR36","unstructured":"Moncivaiz, A. & Alexander, D. CD4 vs. Viral load: what\u2019s in a Number. (2019)."},{"key":"58927_CR37","doi-asserted-by":"crossref","unstructured":"Waritu, N. C., Nair, S. K. P., Usure, R. E. & Jemal, M. J. F. M. Serum uric acid and high-sensitivity C-reactive protein levels among people living with HIV on dolutegravir and ritonavir-boosted atazanavir-based antiretroviral therapy: A comparative cross-sectional study. 11, 1370725 (2024).","DOI":"10.3389\/fmed.2024.1370725"},{"key":"58927_CR38","doi-asserted-by":"crossref","unstructured":"Strauss, K-L-E., Phoswa, W. N., Hanser, S. & Mokgalaboni, K. J. P. HIV infection and antiretroviral therapy impair liver function in people living with HIV: Systematic review and meta-analysis. 18(7), 955 (2025).","DOI":"10.3390\/ph18070955"},{"issue":"1","key":"58927_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12981-025-00817-6","volume":"22","author":"S Suriya","year":"2025","unstructured":"Suriya, S. & Wanitchakorn, S. Prevalence and risk factors of adverse drug events with dolutegravir-based regimens among Thai people living with HIV: a retrospective cohort study. AIDS Res. therapy. 22 (1), 119 (2025).","journal-title":"AIDS Res. therapy"},{"key":"58927_CR40","doi-asserted-by":"crossref","unstructured":"Zemariam, A. B., Tadesse, Y. B. & Kassaw, A. T. Prevalence and Patterns of Adverse Drug Events Among Adult Patients with Human Immune Virus Infection on Dolutegravir-Based Antiretroviral Drug Regimens in Amhara Comprehensive Specialized Hospitals, Northwest Ethiopia: A Multicenter Retrospective Follow-Up Study Vol. 15, 271\u2013278 (HIV\/AIDS, 2023). (Auckland, NZ).","DOI":"10.2147\/HIV.S411948"},{"issue":"19","key":"58927_CR41","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","volume":"369","author":"SL Walmsley","year":"2013","unstructured":"Walmsley, S. L. et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N. Engl. J. Med. 369 (19), 1807\u20131818 (2013).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"58927_CR42","doi-asserted-by":"publisher","first-page":"e0324360","DOI":"10.1371\/journal.pone.0324360","volume":"20","author":"S Badu Nyarko","year":"2025","unstructured":"Badu Nyarko, S. et al. Viral kinetics among persons living with HIV (PLWH) on Dolutegravir-based antiretroviral Regimen: A retrospective and prospective analysis from selected HIV clinics in Ghana. PLoS One. 20 (5), e0324360 (2025).","journal-title":"PLoS One"},{"key":"58927_CR43","unstructured":"Suffrin, J. et al. Presumed severe hepatocellular toxicity after initiation on a dolutegravir-based HIV treatment regimen in Rural Malawi: A case report. 2098. (2022)."},{"key":"58927_CR44","doi-asserted-by":"crossref","unstructured":"Godfrey Mutashambara Rwegerera, M. R., Vimbai Mudhina, M. T., Simone, M. & Sefo, S. B. Dolutegravir induced sub-acute hepatic failure in HIV positive treatment na\u00efve man in Botswana. Case Rep. Intern. Med. 6(4) (2019).","DOI":"10.5430\/crim.v6n4p5"},{"issue":"3","key":"58927_CR45","doi-asserted-by":"publisher","first-page":"ofx122","DOI":"10.1093\/ofid\/ofx122","volume":"4","author":"ES Christensen","year":"2017","unstructured":"Christensen, E. S., Jain, R. & Roxby, A. C. Abacavir\/Dolutegravir\/Lamivudine (Triumeq)-Induced Liver Toxicity in a Human Immunodeficiency Virus-Infected Patient. Open. forum Infect. Dis. 4 (3), ofx122 (2017).","journal-title":"Open. forum Infect. Dis."},{"key":"58927_CR46","doi-asserted-by":"crossref","unstructured":"Nhean, S., Yoong, D., Wong, D. K., Gough, K. & Tseng, A. L. Probable hepatotoxicity with dolutegravir: report of two cases and review of the literature. 33(7), 1261\u20131263 (2019).","DOI":"10.1097\/QAD.0000000000002191"},{"key":"58927_CR47","doi-asserted-by":"crossref","unstructured":"Raffi, F. et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. 381(9868), 735\u2013743 (2013).","DOI":"10.1016\/S0140-6736(12)61853-4"},{"key":"58927_CR48","doi-asserted-by":"crossref","unstructured":"Sax, P. E. et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. 4(4), e154\u2013e60 (2017).","DOI":"10.1016\/S2352-3018(17)30016-4"},{"key":"58927_CR49","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/B978-0-12-387817-5.00040-6","volume-title":"Drug-Induced Liver Disease (Third Edition)","author":"JH Hoofnagle","year":"2013","unstructured":"Hoofnagle, J. H. Chapter 40 - LiverTox: A Website on Drug-Induced Liver Injury. In: (eds Kaplowitz, N. & DeLeve, L. D.) Drug-Induced Liver Disease (Third Edition). Boston: Academic; 725\u2013732. (2013)."},{"key":"58927_CR50","doi-asserted-by":"crossref","unstructured":"Bessone, F. et al. Contreras FJAoh. Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver. 24, 100321 (2021).","DOI":"10.1016\/j.aohep.2021.100321"},{"issue":"8","key":"58927_CR51","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1128\/AAC.00292-13","volume":"57","author":"S Castellino","year":"2013","unstructured":"Castellino, S. et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob. Agents Chemother. 57 (8), 3536\u20133546 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"58927_CR52","doi-asserted-by":"crossref","unstructured":"Parvez, M. M., Kaisar, N. & Shin, J-G-J-J-A-B-E-T. Role of drug metabolic enzymes and transporters in drug-drug interactions between antiretroviral and antituberculosis drugs. 1(1), 17\u201324 (2018).","DOI":"10.5455\/jabet.d2"},{"key":"58927_CR53","doi-asserted-by":"crossref","unstructured":"Yu, S. et al. Age-related differences in drug-induced liver injury: a retrospective single-center study from a large liver disease specialty hospital in China, 2002\u20132022. 18(4), 1202\u20131213 (2024).","DOI":"10.1007\/s12072-024-10679-1"},{"issue":"5","key":"58927_CR54","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s10620-007-9999-6","volume":"53","author":"RK Sterling","year":"2008","unstructured":"Sterling, R. K., Chiu, S., Snider, K. & Nixon, D. The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections. Dig. Dis. Sci. 53 (5), 1375\u20131382 (2008).","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"58927_CR55","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s12876-022-02305-x","volume":"22","author":"LE Abongwa","year":"2022","unstructured":"Abongwa, L. E. et al. Risk factors of severe hepatotoxicity among HIV-1 infected individuals initiated on highly active antiretroviral therapy in the Northwest Region of Cameroon. BMC Gastroenterol. 22 (1), 286 (2022).","journal-title":"BMC Gastroenterol."},{"issue":"2","key":"58927_CR56","doi-asserted-by":"publisher","first-page":"147","DOI":"10.35946\/arcr.v38.2.01","volume":"38","author":"NA Osna","year":"2017","unstructured":"Osna, N. A., Donohue, T. M. Jr. & Kharbanda, K. K. Alcoholic Liver Disease: Pathogenesis and Current Management. Alcohol research: Curr. reviews. 38 (2), 147\u2013161 (2017).","journal-title":"Alcohol research: Curr. reviews"},{"issue":"3","key":"58927_CR57","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40262-024-01466-0","volume":"64","author":"NN Ngcobo","year":"2025","unstructured":"Ngcobo, N. N. Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A Review. Clin. Pharmacokinet. 64 (3), 335\u2013367 (2025).","journal-title":"Clin. Pharmacokinet."},{"key":"58927_CR58","doi-asserted-by":"crossref","unstructured":"Yimer, G. et al. Aseffa AJPo. Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients. 3(3), e1809 (2008).","DOI":"10.1371\/journal.pone.0001809"},{"key":"58927_CR59","doi-asserted-by":"crossref","unstructured":"Mataranyika, P. et al. Liver enzyme elevations in a cohort of HIV\/AIDS patients on first-line antiretroviral therapy in Namibia: findings and implications. 54(1), 49\u201356 (2018).","DOI":"10.1016\/j.ajme.2017.03.002"},{"key":"58927_CR60","doi-asserted-by":"crossref","unstructured":"Mugusi, S. F. et al. Sudfeld CRJJotIAoPoAC. Risk factors for alanine aminotransferase elevations in a prospective cohort of HIV-infected Tanzanian adults initiating antiretroviral therapy. 18:2325958219884939 (2019).","DOI":"10.1177\/2325958219884939"},{"key":"58927_CR61","doi-asserted-by":"crossref","unstructured":"Sulkowski, M. S., Thomas, D. L., Chaisson, R. E. & Moore, R. D. J. J. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. 283(1), 74\u201380 (2000).","DOI":"10.1001\/jama.283.1.74"},{"issue":"3","key":"58927_CR62","doi-asserted-by":"publisher","first-page":"217","DOI":"10.4314\/ejhs.v26i3.4","volume":"23","author":"W Mulu","year":"2013","unstructured":"Mulu, W., Gidey, B., Chernet, A., Alem, G. & Abera, B. Hepatotoxicity and associated risk factors in HIV-infected patients receiving antiretroviral therapy at Felege Hiwot Referral Hospital, Bahirdar, Ethiopia. Ethiop. J. health Sci. 23 (3), 217\u2013226 (2013).","journal-title":"Ethiop. J. health Sci."},{"issue":"3","key":"58927_CR63","first-page":"229","volume":"33","author":"S Barve","year":"2010","unstructured":"Barve, S. et al. Focus on the liver: alcohol use, highly active antiretroviral therapy, and liver disease in HIV-infected patients. Alcohol Res. health: J. Natl. Inst. Alcohol Abuse Alcoholism. 33 (3), 229\u2013236 (2010).","journal-title":"Alcohol Res. health: J. Natl. Inst. Alcohol Abuse Alcoholism"},{"issue":"1","key":"58927_CR64","first-page":"286","volume":"22","author":"LE Abongwa","year":"2022","unstructured":"Abongwa, L. E. et al. Bella SJBg. Risk factors of severe hepatotoxicity among HIV-1 infected individuals initiated on highly active antiretroviral therapy in the Northwest. Region Cameroon. 22 (1), 286 (2022).","journal-title":"Region Cameroon"},{"issue":"4","key":"58927_CR65","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1086\/649922","volume":"50","author":"H Kovari","year":"2010","unstructured":"Kovari, H. et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. Clin. Infect. diseases: official publication Infect. Dis. Soc. Am. 50 (4), 502\u2013511 (2010).","journal-title":"Clin. Infect. diseases: official publication Infect. Dis. Soc. Am."},{"issue":"4","key":"58927_CR66","first-page":"321","volume":"21","author":"JC Fern\u00e1ndez-Checa","year":"1997","unstructured":"Fern\u00e1ndez-Checa, J. C., Kaplowitz, N., Colell, A. & Garc\u00eda-Ruiz, C. Oxidative stress and alcoholic liver disease. Alcohol health Res. world. 21 (4), 321\u2013324 (1997).","journal-title":"Alcohol health Res. world"},{"issue":"6","key":"58927_CR67","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00204-009-0432-0","volume":"83","author":"AI Cederbaum","year":"2009","unstructured":"Cederbaum, A. I., Lu, Y. & Wu, D. Role of oxidative stress in alcohol-induced liver injury. Arch. Toxicol. 83 (6), 519\u2013548 (2009).","journal-title":"Arch. Toxicol."},{"key":"58927_CR68","doi-asserted-by":"crossref","unstructured":"Ngongondo, M. et al. Hepatotoxicity during isoniazid preventive therapy and antiretroviral therapy in people living with HIV with severe immunosuppression: A secondary analysis of a multi-country open-label randomized controlled clinical trial. J. Acquired Immune Deficiency Syndromes 78(1), 54\u201361 (1999).","DOI":"10.1097\/QAI.0000000000001641"},{"key":"58927_CR69","doi-asserted-by":"crossref","unstructured":"Russom, M. et al. Perspectives. Serious hepatotoxicity following use of isoniazid preventive therapy in HIV patients in Eritrea. 6(4), e00423. (2018).","DOI":"10.1002\/prp2.423"},{"issue":"6","key":"58927_CR70","first-page":"384","volume":"6","author":"L Nsobya","year":"2015","unstructured":"Nsobya, L. et al. Isoniazid Preventive Therapy Associated Hepatotoxicity among Children Living with HIV: Descriptive Case Series at Mildmay Uganda HIV\/AIDS Clinic. Uganda 6 (6), 384\u2013391 (2015).","journal-title":"Uganda"},{"issue":"11","key":"58927_CR71","first-page":"e74445","volume":"16","author":"A Ntchana","year":"2024","unstructured":"Ntchana, A. & Muhumza, R. Use of N-Acetylcysteine in the Management of Isoniazid-Induced Liver Injury in a Tuberculosis Patient: A Case Report. Cureus 16 (11), e74445 (2024).","journal-title":"Cureus"},{"key":"58927_CR72","doi-asserted-by":"crossref","unstructured":"Schiuma, M. et al. NAT2 Acetylation status predicts hepatotoxicity during antituberculosis therapy: Cumulative risk analysis of a multiethnic cohort. Int. J. Mol. Sci. 26(8). (2025).","DOI":"10.3390\/ijms26083881"},{"key":"58927_CR73","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-3-642-00663-0_7","volume-title":"Adverse Drug Reactions","author":"A Srivastava","year":"2010","unstructured":"Srivastava, A. et al. Role of Reactive Metabolites in Drug-Induced Hepatotoxicity. In: (ed Uetrecht, J.) Adverse Drug Reactions. Berlin, Heidelberg: Springer Berlin Heidelberg; 165\u2013194. (2010)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58927-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58927-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58927-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:31:53Z","timestamp":1790206313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58927-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["58927"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-58927-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]},"assertion":[{"value":"28 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical clearance with reference number SOM\/87\/02\/24 was obtained from the ethical review committee of the Debre Markos University, and a letter of cooperation was obtained from the DMCSH medical director\u2019s office before the actual data collection started. Written informed consent was obtained from the study participants. Participants had a full right to continue or withdraw from the study. Participants\u2019 personal information was kept with strict confidentiality throughout the study. This study was conducted in accordance with Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"29681"}}